Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) EBITDA Margin (2021 - 2025)

InMed Pharmaceuticals has reported EBITDA Margin over the past 5 years, most recently at 256.36% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 5470.0% year-over-year to 256.36%; the TTM value through Dec 2025 reached 174.33%, down 1245.0%, while the annual FY2025 figure was 159.76%, 1747.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 256.36% at InMed Pharmaceuticals, down from 162.54% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 20.43% in Q2 2023 and troughed at 1615.6% in Q4 2021.
  • A 5-year average of 460.38% and a median of 193.24% in 2023 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 150844bps in 2023 and later crashed -13769bps in 2024.
  • Year by year, EBITDA Margin stood at 1615.6% in 2021, then surged by 72bps to 447.25% in 2022, then surged by 71bps to 131.49% in 2023, then plummeted by -53bps to 201.65% in 2024, then dropped by -27bps to 256.36% in 2025.
  • Business Quant data shows EBITDA Margin for INM at 256.36% in Q4 2025, 162.54% in Q3 2025, and 138.56% in Q2 2025.